Lombard Medical Technologies PLC : - Change of Nominated Adviser and Broker

Lombard Medical Technologies PLC

("Lombard Medical" or "the Company")

Change of Nominated Adviser and Broker

London, UK, 17 January 2012 - Lombard Medical Technologies PLC (AIM: LMT), the specialist medical technology company focussed on innovative vascular products, is pleased to announce the appointment of Collins Stewart Europe Limited as Nominated Adviser and Broker to the Company with immediate effect.

- Ends -

About Lombard Medical

Lombard Medical Technologies PLC (AIM: LMT), is a medical device company focused on device solutions for the $1.1 billion dollar per annum abdominal aortic aneurysm (AAA) repair market. AAAs are a balloon-like enlargement of the aorta which, if left untreated, may rupture and cause death.  Approximately 4.5 million people are living with AAAs in the developed world and each year 600,000 new cases are diagnosed. The market for endovascular stent grafts for this application is expected to grow to $1.6 billion by 2015.  The Company's lead product, Aorfix™, is an endovascular stent graft which has been specifically designed to solve the problems that exist in treating complex tortuous anatomy which is often present in advanced AAA disease.  Aorfix™ is currently being commercialised in the EU, and has been submitted to the FDA for approval in the U.S.

The Company is headquartered in Oxfordshire, with operations in Ayrshire and Phoenix, USA.

For further information:

Lombard Medical Technologies PLC
Simon Hubbert, Chief Executive Officer	Tel: [phone]
Collins Stewart Europe Limited
Jamie Adams / Mark Dickenson / Lucy Tilley	Tel : [phone]
FTI Consulting
Jonathan Birt/Susan Quigley	Tel : [phone]